Table 5.
Malignant tumours 3-year relative survival and its 95% CI in the Augsburg study region in three time periods (2005/2007, 2008/2010 and 2011/2013) by sex and site—incident cancer cases of the years 2005–2013
| Site (ICD-10) | 2005–2007 | 2008–2010 | 2011–2013 |
| 3-year RES (95% CI) | 3-year RES (95% CI) | 3-year RES (95% CI) | |
| Men (n=14 538) | n=4660 | n=4890 | n=4988 |
| Lip/oral cavity/pharynx (C00–C14) | 45.9 (39.2 to 53.8) | 53.5 (46.2 to 61.8) | 61.6 (54.5 to 69.8) |
| Oesophagus (C15) | 25.2 (17.4 to 36.4) | 30.9 (22.6 to 42.4) | 38.0 (29.2 to 49.4) |
| Stomach (C16) | 48.8 (41.2 to 57.9) | 36.9 (29.9 to 45.7) | 44.7 (37.4 to 53.5) |
| Colorectum (C18–C21) | 74.7 (71.0 to 78.5) | 74.5 (70.7 to 78.5) | 76.6 (72.8 to 80.6) |
| Liver (C22) | 20.2 (13.7 to 29.8) | 16.8 (10.7 to 26.1) | 24.8 (18.2 to 34.0) |
| Pancreas (C25) | 9.0 (5.2 to 15.6) | 10.0 (5.9 to 17.0) | 14.9 (9.9 to 22.2) |
| Lung (C33–C34) | 19.4 (16.0 to 23.5) | 22.8 (19.4 to 26.7) | 27.1 (23.6 to 31.3) |
| Malignant melanoma of the skin (C43) | 94.1 (89.1 to 99.4) | 96.9 (93.1 to 100.8) | 99.2 (95.2 to 103.3) |
| Prostate (C61) | 98.1 (96.3 to 100.0) | 94.2 (91.9 to 96.6) | 98.0 (95.9 to 100.2) |
| Testis (C62) | 97.3 (93.6 to 101.2) | 97.9 (94.5 to 101.5) | 97.2 (93.4 to 101.2) |
| Kidney (C64) | 82.0 (74.8 to 90.0) | 80.0 (72.8 to 88.0) | 77.9 (71.2 to 85.2) |
| Urinary bladder (C67) | 60.0 (51.1 to 70.5) | 60.1 (51.7 to 69.8) | 73.9 (66.2 to 82.5) |
| Central nervous system (C70–C72) | 38.2 (28.1 to 52.0) | 22.5 (15.0 to 33.6) | 20.0 (12.6 to 31.7) |
| CUP (C80) | 13.3 (7.8 to 22.7) | 22.0 (14.3 to 33.9) | 23.4 (15.8 to 34.7) |
| Non-Hodgkin’s lymphoma (C82–C88) | 71.9 (64.5 to 80.2) | 79.2 (72.6 to 86.3) | 77.9 (70.9 to 85.7) |
| Leukaemia (C91–C95) | 68.5 (59.9 to 78.3) | 69.9 (61.8 to 79.0) | 67.0 (59.2 to 75.8) |
| Women (n=13 342) | n=4160 | n=4571 | n=4611 |
| Lip/oral cavity/pharynx (C00–C14) | 60.4 (47.7 to 76.4) | 67.1 (55.0 to 81.9) | 83.0 (73.5 to 93.7) |
| Stomach (C16) | 46.7 (38.3 to 57.1) | 42.4 (34.0 to 53.0) | 55.2 (45.2 to 67.3) |
| Colorectum (C18–C21) | 73.0 (68.8 to 77.5) | 74.1 (69.8 to 78.7) | 77.6 (73.4 to 82.0) |
| Pancreas (C25) | 10.0 (5.5 to 18.3) | 12.1 (7.8 to 18.9) | 11.5 (7.4 to 17.8) |
| Lung (C33–C34) | 26.9 (21.6 to 33.5) | 29.1 (24.2 to 35.1) | 25.7 (20.9 to 31.7) |
| Malignant melanoma of the skin (C43) | 99.5 (96.2 to 102.8) | 97.4 (94.1 to 100.7) | 97.1 (93.3 to 101.0) |
| Breast (C50) | 89.9 (87.9 to 92.0) | 92.7 (91.0 to 94.6) | 95.0 (93.3 to 96.7) |
| Cervix uteri (C53) | 72.1 (62.9 to 82.6) | 72.2 (62.8 to 83.1) | 77.3 (69.3 to 86.3) |
| Corpus uteri (C54–C55) | 82.7 (77.3 to 88.5) | 87.3 (82.1 to 92.8) | 88.4 (83.4 to 93.6) |
| Ovary (C56) | 41.7 (34.9 to 49.9) | 52.4 (45.3 to 60.6) | 66.3 (58.6 to 75.0) |
| Kidney (C64) | 82.8 (74.3 to 92.2) | 73.8 (64.8 to 84.0) | 75.9 (66.8 to 86.2) |
| Central nervous system (C70–C72) | 39.1 (27.9 to 54.8) | 28.0 (18.6 to 42.1) | 27.4 (18.8 to 40.1) |
| Thyroid (C73) | 94.5 (90.3 to 99.0) | 96.4 (92.0 to 101.0) | 98.6 (95.3 to 102.0) |
| CUP (C80) | 20.0 (13.1 to 30.6) | 16.0 (9.4 to 27.3) | 17.4 (10.7 to 28.4) |
| Non-Hodgkin’s lymphoma (C82–C88) | 74.9 (67.4 to 83.4) | 76.4 (69.5 to 84.1) | 75.0 (67.7 to 83.2) |
| Leukaemia (C91–C95) | 64.8 (55.6 to 75.5) | 69.2 (60.4 to 79.3) | 58.0 (48.0 to 70.0) |
RES, relative survival (%)